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ABSTRACT
Objective: This study aimed to investigate the association between treatment manners, glycemic control, and C-reactive protein (CRP) serum level in 
patients in receipt of anti-diabetic drugs (ADM) alone or ADM by means of antihypertensive (AHT) drugs in Basra.
Methods: Patients in receipt of ADM or ADM with AHT drugs, not suffering from complications, were recruited from Al-Mawanee General Hospital 
in Basra. Socioeconomic characteristics, blood pressure (BP), and treatment tactics were recorded. Blood sample was obtained to gauge glycated 
hemoglobin (HbA1c), lipids profile, and high responsive (high-sensitive CRP [hs-CRP]).
Results: A total of 26 men and 50 women were involved. Lower mean HbA1c was found in patients in receipt of ADM with AHT drugs compared with 
those on ADM drugs merely (p=0.0013). Lower denote systolic BP (p<0.0001) and diastolic BP (p=0.0078) were established in patients receiving 
ADM drugs only compared with persons receiving ADM with AHT drugs. Lower denote hs-CRP was found in women receiving ADM with AHT drugs 
compare with those on ADM drugs only. Treatment manners had no effect on denote hs-CRP in men and women receiving ADM with AHT drugs; 
however, there was a significant direct association of hs-CRP with HbA1c (p=0.002) and triglycerides (p=0.009), but inversely with high-density 
lipoprotein cholesterol (p=0.011) in women receiving ADM drugs merely.
Conclusion: High level of hs-CRP is associated with poor glycemic manage and dyslipidemia, therefore, consequently greater than before cardiovascular 
risk. Due to its value as a danger predictor, hs-CRP be supposed to be included in custom monitoring of type 2 diabetic patients.
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INTRODUCTION
In Iraq, the high rate of occurrence of diabetes and hypertension has been 
documented. Diabetes plus hypertension is the two main risk factors in 
the growth of ischemic heart disease, cardiac hypertrophy, and cardiac 
failure. Cardiovascular disease is the most common cause of mortality 
in the world. Previous studies have demonstrated that persons with 
diabetes [1] and hypertension [2,3] have higher levels of C-reactive 
protein (CRP) compare with individuals without these conditions in the 
general population. Increased risk of cardiovascular disease has also be 
associated with an increased level of CRP [4,5]. CRP mixture and secretion 
are mainly in hepatic cells [6]. It is regulated by the action of lots of 
activated cytokines such as interleukin-6 (IL-6), IL-1, and tumor necrosis 
factor-alpha [7]. CRP is a sign of universal inflammation in the blood [8]. 
The normal plasma level of CRP in a fit inhabitants without proof of acute 
inflammation is 2 mg/L or less [9]. There is a rapid rise in the circulating 
CRP by as much as 3000-fold in answer to inflammation, infection, or 
acute hankie injuries, which drop rapidly at what time inflammation or 
injury is determined [10]. Many studies are focused on the association of 
chronic elevation of CRP with an increased risk of cardiovascular disease 
and atherosclerosis [11-14]. If CRP is worried about the pathophysiology 
of cardiovascular illness, it could be accepted that lower CRP levels 
would reduce the development of the disease and its complications. 
CRP causes atherosclerosis by various mechanism, such as the release 
of reactive oxygen species (ROS), CRP increases the generation of ROS 
by monocytes and neutrophils [15,16] directly. ROS have been concerned 
in the beginning and continuance of atherosclerosis [17]. Furthermore, 
CRP increases the look of adhesion molecules [18]. Furthermore, CRP has 
been worried about the destabilization of atherosclerotic plaques [19]. 
Moreover, CRP can arbitrate the uptake of low-density lipoprotein into 
macrophages to form foam cell [20].
The aim of this study was to investigate the association between 
drug treatments, glycemic manage, and serum height of CRP in Iraqi 
patients receiving anti-diabetic drugs (ADM) drugs or ADM with 
antihypertensive (AHT) drugs.
METHODS
This study was conducted during the era as of February to May 2018, 
and the patients were selected during their visit to Diabetes Endocrine 
and Metabolism Center in Al-Mawanee all-purpose Hospital in Basra. 
The Institutional Ethical Committee accepted the study, and informed 
consent was obtained from the subjects. Patients getting ADM drugs or 
ADM with AHT drugs, not suffering from complications, were recruited. 
A total of 76 diabetic patients aged between 42 and 67 years were 
included in this study, 50 patients were female and 26 were male. Forty-
two patients using ADM with AHT drugs, from which 30 were female and 
12 were males. The other 34 patients are using ADM drugs only. Patients 
were excluded as of the learn if they were type 1 diabetic patients or 
if they have any cognitive problems. Socioeconomic characteristics, 
blood pressure (BP), and treatment plans were recorded. Fasting blood 
sample be obtained to measure glycated hemoglobin (HbA1c), lipids 
profile, and high-sensitive CRP (hs-CRP). HbA1c up to 7% reflected 
adequate glycemic control, as HbA1c >7% reflected poor glycemic 
manage, as optional by the American Diabetic Association rule [21]. 
Hypertension was distinct as a systolic BP >140 mmHg or diastolic BP 
>90 mmHg, or modern use of AHT drug treatment [22].
Laboratory investigations
HbA1C was measured by D-10 double Program Bio-Rad Laboratories, 
Inc., Hercules, CA 94547, 220-020, California, USA. D-10 Dual Program 
is based on chromatographic separation of the analytes by ion-exchange 
(high-performance liquid chromatography). Hs-CRP was measured by 
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Cobas Integra 400. Serum lipids (cholesterol, triglycerides, and high-
density lipoprotein cholesterol [HDL-C]) were assayed using automated 
enzymatic methods (Dimension Vista 1500T Intelligent Lab System 
from Siemens Company-Germany) at the biochemistry laboratory.
Statistical analysis
Statistical analysis was performed by GraphPad Prism software 
(version 7.0, GraphPad Software, Inc., San Diego, CA). Descriptive 
statistics, such as mean ± standard deviation, were calculated for all 
estimated parameters. Comparison between two means was performed 
using unpaired Student t-test for normally distributed parameters. 
Associations between variables were examined using Pearson’s 
correlation coefficients. All p values that were <0.05 were considered 
significantly different.
RESULTS
A total of 26 men and 50 women be recruited. Inferior mean HbA1c was 
found in patients receiving ADM with AHT drugs compare with those 
on ADM drugs only (p=0.0013). Lower denote systolic BP (p<0.0001) 
and diastolic BP (p=0.0078) were found in patients receiving ADM 
drugs only compared with patients receiving ADM with AHT drugs. 
Lower mean hs-CRP was found in women in receipt of ADM with AHT 
drugs compared with those on ADM drugs only (Table 1). Furthermore, 
the main AHT drugs used by the patients involved in this study were 
angiotensin receptor blockers (losartan and candesartan), angiotensin-
converting enzyme inhibitors (captopril and enalapril), calcium 
channel blockers (CCBs) (amlodipine and diltiazem), and β-blocker 
drug carvedilol. Furthermore, the main ADM drugs used by the patients 
involved in this study were glibenclamide, glimepiride, metformin, and 
insulin.
Treatment manner had no effect on mean hs-CRP in men; however, there 
was a significant direct correlation of hs-CRP with HbA1c (p=0.002) 
and triglycerides (p=0.009), but inversely with HDL-C (p=0.011) in 
women receiving ADM drugs only. Furthermore, the treatment manner 
had no effect on mean hs-CRP in men and women receiving ADM with 
AHT drugs (Table 2).
DISCUSSION
This study be designed to investigate the association between drug 
treatments, glycemic control, and serum level of CRP in Iraqi patients 
receiving ADM drugs or ADM with AHT drugs.
Diabetes mellitus is associated with numerous complications. 
Hyperglycemia increased BP, dyslipidemia, oxidative stress, and 
inflammation are all characteristics of type 2 diabetes mellitus and are 
concerned in the development of vascular complications [23,24] so that 
control of diabetes leads to decreased risk of these complications. Most of 
the diabetic patients involved in our study were uncontrolled regardless of 
which ADM drug treatment was used. This study revealed that the lower 
mean of HbA1c was found in patients receiving ADM with AHT drugs 
compared with those on ADM drugs only. Few studies are found concerned 
with the combined effects of ADM with AHT drugs on the HbA1c level.
The previous study revealed that the adverse effect of some AHT drugs 
on blood glucose homeostasis may influence their cardiovascular 
protection role. Different classes of AHT drugs have different effects on 
blood glucose homeostasis. Some of the AHT drugs such as angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, some of the 
CCBs such as azelnidipine and manidipine, and some of the β-blockers 
such as carvedilol and nebivolol revealed to have advantageous effects 
on glucose metabolism. Conversely, diuretics and other β-blockers have 
an unfavorable effect on glucose metabolism [25].
Lower mean hs-CRP be found in women receiving ADM with AHT drugs 
compared with those on ADM drugs only. Treatment manners had no 
effect on mean hs-CRP in men; however, there was a significant direct 
correlation of hs-CRP with HbA1c and triglycerides, but inversely with 
HDL-C in women receiving ADM drugs only. Furthermore, the treatment 
manners had no effect on mean hs-CRP in men and women receiving 
ADM with AHT drugs.
CONCLUSION
These results indicated that high levels of hs-CRP are associated with 
poor glycemic control and dyslipidemia, therefore, consequently 
increased cardiovascular risk.
Table 1: Measured hs-CRP, HbA1c, and BP according to treatment manner (Mean±STDEV) of type 2 diabetic patients or type 2 diabetes 
with hypertension patients
Variables Mean±STDEV users of ADM onlyA Mean±STDEV users of ADM and AHTB p value
Age (years) 54.1±6.3 56.6±5.7 0.0738
HbA1C (%) 10.36±2.3 8.86±1.6 0.0013
Systolic BP (mmHg) 122.7±6.7 149.5±18.8 <0.0001
Diastolic BP (mmHg) 80.59±7.3 85.2±7.3 0.0078
hs-CRP (mg/L)
Male 2.00±0.9 1.8±0.8 0.3089
Female 6.7±4.5 2.6±1.4 <0.0001
Table 2: Correlations between hs-CRP with HbA1c, lipid profile, and BP in men and women of type 2 diabetic patients or type 2 diabetes 
with hypertension patients


















































ATotal number=34, men (14), women (20). BTotal number=42, men (12), women (30). ADM: Anti-diabetic, AHT: Antihypertensive; STDEV: Standard deviation,                  HbA1c: Glycated hemoglobin, hs-CRP: Highly sensitive, CRP: Statistically significant values are shown in bold font (significance p<0.05), BP: Blood pressure
HbA1c Cholesterol TG HDL-C SBP DBP
DM: Diabetes mellitus, HT: Hypertension, HbA1c: Glycated hemoglobin, TG: Triglyceride, HDL-C: High-density lipoprotein cholesterol, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure, hs-CRP: Highly sensitive, CRP: Statistically significant values are shown in bold font (significance p<0.05)
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Due to the valuable effect of hs-CRP as a cardiovascular risk predictor, 
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